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Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain
and altered bowel habit, and often associates with other gastrointestinal symptoms such
as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal
symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also
frequently coexists with conditions that may also involve central sensitization processes,
such as ﬁbromyalgia, irritable bladder disorder, and chronic cough. This review examines
the evidence to date on gabapentin and pregabalin which may support further and con-
tinued research and development of the α2δ ligands in disorders characterized by visceral
hypersensitivity, such as IBS.The distribution of the α2δ subunit of the voltage-gated cal-
cium channel, possible mechanisms of action, pre-clinical data which supports an effect
on motor–sensory mechanisms and clinical evidence that points to potential beneﬁts in
patients with IBS will be discussed.
Keywords: α2δ ligands, gabapentin, pregabalin, irritable bowel syndrome, visceral sensitivity, central sensitization,
peripheral sensitization, motility
INTRODUCTION
ABDOMINAL PAIN AND VISCERAL HYPERSENSITIVITY
Abdominal pain and discomfort along with altered bowel habit
are integral to the diagnosis of irritable bowel syndrome (IBS).
Although disordered bowel habit can often be improved in these
patients, efﬁcacious treatment of pain, abdominal discomfort,
and associated symptoms, such as bloating, remains challeng-
ing. The identiﬁcation and development of new drugs to treat
these symptoms has been largely unsuccessful and remains prob-
lematic, probably linked to the complexity of the functional gas-
trointestinal disorders (FGIDs) in which multiple factors appear
to contribute to their equally multifarious pathophysiology. For
example,geneticpredisposition,infection,andtraumaticeventsin
early life may all predispose individuals to developing IBS, whilst
chronic stress, psychological symptoms, and maladaptive coping
mechanisms can increase the frequency and severity of symptoms
(Levy et al., 2006; Chitkara et al., 2008; Saito and Talley, 2008;
Spiller and Garsed, 2009). Pathophysiologies identiﬁed to date
include gastrointestinal dysmotility, abnormalities in the inﬂam-
matory/immune system, increased intestinal permeability, unsta-
ble or altered enteric ﬂora, psychopathology, visceral and somatic
hypersensitivity,and abnormal CNS processing (Longstreth et al.,
2006; Spiller et al., 2007). Although not all abnormalities are
present in all patients, visceral hypersensitivity which often asso-
ciates with the symptoms of pain (Posserud et al., 2007) and
bloating (Posserud et al., 2007; Agrawal et al., 2008) and which is
oftenexacerbatedbystress,isthoughtbymanytobeadeterminant
orbiologicalmeasureof IBS(Mertzetal.,1995;Bouinetal.,2002).
For example, Mertz et al. (1995) showed altered rectal perception
in almost all IBS patients in the form of either lowered sensory
thresholds,increased sensation intensity or altered viscerosomatic
referral, whilst Bouin et al. (2002) suggested that a pain threshold
of less than 40mmHg in the rectum correctly identiﬁed IBS from
non-IBS subjects. In addition, whilst only approximately half of
IBS patients appear to exhibit lowered rectal sensory thresholds to
balloon distension (Whitehead and Palsson, 1998; Posserud et al.,
2007), almost all patients (70%) show hypersensitivity elsewhere
in the gastrointestinal tract, especially in the jejunum (Francis
etal.,1995;Hammondsetal.,1998).Moreover,inthelatterstudies
(Francis et al., 1995; Hammonds et al., 1998) within the group as
a whole,and especially in those subjects with diarrhea,lower pain
thresholdswereobservedthroughouttheentireGItractcompared
with healthy controls.
CENTRAL SENSITIZATION
These observations of pan-gastrointestinal visceral hypersensi-
tivity and increased viscerosomatic referral, along with reported
increases in expression of extra-intestinal symptoms such as
headache, dyspareunia, heartburn, muscle pain and back pain
(Whorwelletal.,1986;MayerandGebhart,1994),andpresenceof
ﬁbromyalgia in some patients (Whitehead et al., 2002; Almansa
et al., 2009) are consistent with a widespread aberrant central
processing of pain (central sensitization) in these patients. Fur-
ther support is provided by the observations that whilst healthy
volunteers exhibit an inhibition of the somatic nociceptor ﬂex-
ion reﬂex (R-III) to slow ramp distension of the rectum, IBS
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patients exhibit a facilitation of this reﬂex, suggesting enhanced
spinal processing in IBS (Cofﬁnetal.,2004). In addition,there are
an increasing number of studies suggesting that IBS patients may
also be hypersensitive to somatic stimuli. One such study,showed
hypersensitivity to rectal balloon distension and cutaneous ther-
malstimulationofthehandandfootinIBScomparedwithcontrol
subjects(Verneetal.,2001).Interestinglyfoothypersensitivitywas
greaterthanhandhypersensitivity,suggestinggreaterconvergence
and overlap of rectal and foot afferents at common lumbosacral
levels (greater central hyperalgesia) than rectal and hand afferents
at the levels of the cervical spinal (Verne et al., 2001).
POSSIBLE SYNERGISTIC MECHANISMS
Along with the spinal (central) sensitization,other possible syner-
gisticmechanismsofvisceralhypersensitivityincludedisturbances
in the cognitive and emotional aspects of pain (e.g., hypervig-
ilance, somatization, catastrophizing, depression), alterations in
descending excitatory and inhibitory pathways (e.g., diffuse nox-
iousinhibitorycontrol,DNIC),andsensitizationofafferentnerves
(e.g.,peripheralsensitizationduetoforexamplemucosalinsult).A
quantitative meta-analysis of functional neuroimaging studies in
IBS patients during rectal distension showed greater recruitment
of attentional(lateralprefrontalcortex),affective(ventralanterior
cingulated cortex [ACC], amygdala, dorsal pons), and homeo-
static afferent circuits (insula, dorsal ACC, thalamus) compared
with controls, with increased regional activity in the insula (INS)
and anterior midcingulate cortex (aMCC) being most commonly
reported (Labus et al., 2009). More recent studies investigating
anatomical differences in the brain between IBS and control sub-
jects have shown morphometric changes in gray matter density
predominantlyinareasinvolvedincognitionandevaluation,with
changes in other areas of the brain being generally explained
by anxiety and depression levels in the IBS patients (Seminow-
icz et al., 2010). In another study by Heymen et al. (2010),i n
which DNIC was assessed in IBS compared with healthy subjects
by measuring the reduction in left hand thermal pain intensity
during counter irritation by submersion of the right hand in 12˚C
water (conditioning stimulus, CS), and controlling for the non-
speciﬁc effects on pain perception, such as distraction from the
CS, psychological symptoms, and cardiovascular reactivity, it was
shown that IBS patients demonstrate deﬁcient DNIC probably
attributedtodisorderedcentralanalgesicmechanisms.Thisdeﬁcit
has subsequently been shown to directly correlate with visceral
hypersensitivity (Piche et al., 2010). Indeed in the morphologi-
cal study described above signiﬁcant reductions in gray matter
density were observed in the periaqueductal gray, an area known
to play a major role in descending pain modulation, which was
independent of anxiety and depression (Seminowicz et al., 2010).
Other studies have shown that peripheral mucosal insults,such as
the presence of inﬂammation, injury or excess acid do not only
increase pain sensitivity at the site of injury (primary hyperalge-
sia/peripheral sensitization) but also at more remote sites in the
gastrointestinal tract (secondary hyperalgesia), via the process of
central sensitization (Anand et al.,2007;Knowles andAziz,2009).
One example in FGIDs, is the observation that pain thresholds to
electrical stimulation were not just reduced at the distal end of
the esophagus where acid was infused but also in the unexposed
proximal esophagus of patients with non-cardiac chest pain, with
this sensitization process being signiﬁcantly magniﬁed and pro-
longed compared with healthy volunteers (Sarkar et al., 2000).
Another possible example is the onset of IBS following GI infec-
tion (post-infectious IBS) where persistent sensitization of the
primaryafferentsduetoforexampleincreasedmastcellsnumbers,
T lymphocytes, and expression interleukin (IL)-1β (peripheral
sensitization), especially in the presence of risk factors such as
depression, hypochondriasis, and adverse life events (Spiller and
Garsed, 2009), could lead to central sensitization and the per-
sistence of symptoms, allodynia (pain to a stimulus that does not
normallyprovokepain),hyperalgesia(increaseinintensityof pain
to a stimulus that normally provokes pain), and dysmotility long
after the resolution of illness.
Thus there appears to be a dyssynergy between the interaction
of peripheral and central pain mechanisms, along with inﬂu-
ences from cognitive and emotional factors, and abnormalities
in descending inhibitory pathways that may all lead to the sen-
sation of abdominal pain and hypersensitivity in IBS. Central
mechanisms perhaps play a pivotal role integrating between these
processes and thus may represent a promising target for the devel-
opment of drugs for the treatment of IBS. For a more detailed
discussion of central, peripheral, and psychological processes in
IBS see the reviewsVan Oudenhove andAziz (2009),Knowles and
Aziz (2009), and Anand et al. (2007).
α2δ BINDING SITES
Gabapentin (Neurontin) was ﬁrst introduced as an antiepileptic
drug but has more recently been used in the treatment of posther-
petic neuralgia, diabetic neuropathy, migraine prophylaxis, and
chronic pain conditions (Taylor, 2009; Tzellos et al., 2010). Pre-
gabalin (Lyrica) is a second-generation compound structurally
related to gabapentin and approved in the US for the manage-
mentof neuropathicpainassociatedwithdiabeticperipheralneu-
ropathy, postherpetic neuralgia, ﬁbromyalgia, and as adjunctive
therapy for adults with partial onset seizures and for generalized
anxiety disorder (GAD). In Europe pregabalin is approved for
the treatment of neuropathic pain, epilepsy, and generalized anx-
iety disorder (Taylor, 2009; Tzellos et al., 2010). It has been, or
is being, assessed in many clinical trials for disorders such as IBS
and neuropathic pain in acute spinal cord injury (see US National
Institute of Health, www.ClinicalTrials.gov). Pregabalin has been
shown to be 2–10 times more potent than gabapentin and to pos-
sessmorelinearpharmacokinetics(Ben-Menachem,2004;Huckle,
2004; Taylor,2009; Tzellos et al.,2010).
Although structurally related to γ-aminobutyric acid (GABA),
a major inhibitory neurotransmitter in the CNS, gabapentin, and
pregabalin are functionally inactive at GABAA, GABAB,o rb e n -
zodiazepine receptors, and are not converted metabolically into
GABAoraGABAreceptoragonist(Ben-Menachem,2004;Huckle,
2004;Taylor,2009;Tzellosetal.,2010).Inaddition,clinicallyeffec-
tiveconcentrationsofgabapentinandpregabalinhavebeenshown
to have no effect on GABA synthesis,uptake or degradation (Ben-
Menachem, 2004; Huckle, 2004; Field et al., 2006; Taylor, 2009;
Tzellos et al.,2010).
Both gabapentin and pregabalin bind with high afﬁnity to
α2δ subunits of voltage-gated calcium channels and this has been
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proposedasalikelysiteoftheiraction.Further,inmicewithmuta-
tions of the α2δ subunits that prevent drug binding, pregabalin
andgabapentinaredevoidof analgesicandanticonvulsantactivity
(Field et al.,2006).Voltage-gated calcium channels are ubiquitous
in the body and are made up of an α1 subunit, which makes up
the ion-conducting pore, coupled together with other subunits
including β, γ, and α2δ. There is great heterogeneity within the
family of α1 subunits, of which 10 members have been described
in mammals (for review; Catterall et al., 2005). The α2δ subunit
appears to play a role not only in the operational characteristics
of individual channels, but also to enhance trafﬁcking of the α1
subunitstothecellmembrane,soinﬂuencingthenumberof func-
tional calcium channels (Hendrich et al., 2008; Mich and Horne,
2008).Theα2δsubunitexistsasfourdistinctsubtypesandtheseare
encoded by four distinct genes (Klugbauer et al., 1999; Qin et al.,
2002). Only subtypes 1 and 2 have been shown to exhibit binding
for gabapentin and pregabalin and therefore might be expected to
underwrite the analgesic, anticonvulsant, and anxiolytic activity
of these drugs (Gong et al.,2001; Qin et al.,2002).
Despite the widespread localization of voltage-gated calcium
channels, the focus of studies to map the distribution of the α2δ
subunit has largely been restricted to tissues of the central ner-
vous system, with few studies exploring the potential for wider
distribution. At both the mRNA and protein level, α2δ-subtype 1
is widely distributed throughout human brain (Gong et al.,2001).
This widespread distribution of mRNA for the α2δ-subtype 1 has
been conﬁrmed in the central nervous system of the rat and was
reported in regions of the CNS involved in cortical processing,
learning and memory, defensive behavior, neuroendocrine secre-
tion, autonomic activation, primary sensory transmission, and
general arousal (Cole et al., 2005). These observations have been
conﬁrmedattheproteinlevelusingimmunostainingwithananti-
bodyspeciﬁcforα2δ-subtype1(TaylorandGarrido,2008).Inthis
study, the most prominently stained regions of the CNS included
those areas involved in pain signaling, including the amygdala,
entorhinalcortex,hippocampus,ACC,andinsula(TaylorandGar-
rido,2008).Inaddition,apopulationof smalldiameterperipheral
sensory neurones in the dorsal root ganglia, together with their
projections to the spinal cord, stained prominently (Taylor and
Garrido, 2008). Immunostaining in the GI tract was also investi-
gated, although only data from the small intestine was reported
showing moderate staining in the smooth muscle (Taylor and
Garrido, 2008). To date, there has been only one report of neu-
ronal α2δ subunit expression in the intestine. In the guinea-pig,
in situ hybridization has revealed the α2δ-subtype 1 localized on
the intrinsic primary afferent neurones of the intestine, where
theyappeartobeassociatedwithN-typecalciumchannels(Need-
ham et al., 2010). In these neurones, pregabalin had inhibitory
effects on both the action potential and the after hyperpolariza-
tion, raising the possibility that pregabalin may be able to reduce
theexcitabilityofthesesensoryneuronesandsopotentiallyinhibit
GI hypersensitivity by an effect at these sites. The distribution of
α2δ-subtype 2 has been less extensively characterized. However,
in the rat, mRNA encoding α2δ-subtype 2 has been shown to be
widely distributed within the CNS, with particularly dense stain-
ing in the brainstem, the periaqueductal gray matter, the spinal
cord,and dorsal root ganglia (Cole et al.,2005). These are regions
known to play an important role in autonomic function and pain
processing. In tissues from human, mRNA for α2δ-subtype 2 was
detected in several brain regions but not in colon or small intes-
tine (Gong et al., 2001). The absence of α2δ-subtype 2 in human
jejunum was also conﬁrmed at the protein level.
The functional consequences of the binding of gabapentin/
pregabalin with the α2δ protein remain controversial. Data from
recombinant systems suggests that the function of the α2δ sub-
unit is heavily dependent on the subtype of α1 protein with
which the α2δ subunit is co-expressed and the cell system into
which the proteins are engineered. However, it is widely accepted
that the mechanism of action of these agents involves a modula-
tion of calcium conductance, but the precise mechanism for this
remains to be elucidated. The modulation of calcium currents
by gabapentin has been demonstrated in several studies of iso-
lated neurones (Stefani et al., 1998; Sutton et al., 2002; van Hooft
et al., 2002), although other studies have struggled to demon-
strate such an effect (Schlicker et al., 1985). More recently, it has
beenproposedthatgabapentinmayexertanactionthroughbind-
ing to the α2δ subunit within the cytosol, rather than at the cell
surface, and that this interaction can over time reduce the traf-
ﬁcking of α1/α2δ complexes to functional sites within the cell
membrane (Hendrich et al., 2008; Mich and Horne, 2008). Thus
gabapentinandpregabalinmayexertarangeofeffects,eitheracute
or chronic, mediated through diverse mechanisms, to modulate
calcium ﬂux in nerve terminals. The consequences of this disrup-
tion of calcium-mediated membrane depolarization have been
investigated extensively. Both gabapentin and pregabalin have
been shown to inhibit the release of a wide range of neurotrans-
mitters including noradrenaline, dopamine, 5-HT, acetylcholine,
glutamate, substance P, and CGRP from isolated slices of brain
and spinal cord from several species following stimulation with
either potassium or capsaicin (Dooley et al., 2000; Patel et al.,
2000;Fehrenbacher et al.,2003;Brawek et al.,2008). However,the
inhibitory effect of gabapentin and pregabalin may be stimulus-
dependant,asillustratedintheneocortex,wherethemagnitudeof
inhibition of the release of noradrenaline was reduced when neu-
rotransmitter release was evoked by electrical stimulation rather
than potassium (Dooley et al., 2000). It has been suggested that
α2δ ligands may only exert their inhibitory effects on neuro-
transmitter release in “sensitized” situations and may exert only
limited effects in situations of normal physiology. For example,
in the spinal cord, gabapentin was only able to exert its presy-
naptic inhibitory inﬂuence on postsynaptic currents in animals
in which experimental diabetic neuropathy had been established
with streptozotocin and not in unsensitized animals (Patel et al.,
2000). Similarly,the pregabalin-mediated reductions in substance
P and CGRP release in the spinal cord of the rat are manifest only
in animals in which inﬂammation had been induced following
pre-treatment with intraplantar Freund’s adjuvant and are absent
in untreated animals (Fehrenbacher et al., 2003).
Morerecently,anadditionalmechanismofactionhasbeensug-
gested for gabapentin and pregabalin. In cell or neuronal cultures
gabapentinandpregabalinwereshowntoinhibittheactivationof
the transcription factor NF-κB evoked by substance P (Park et al.,
2008).Ifconﬁrmedinadditionalstudies,theseobservationsmight
help explain the increased efﬁcacy of gabapentin and pregabalin
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in circumstances of prior inﬂammation or sensitization, which
might be expected to lead to up-regulation of the NF-κB signaling
pathway.
PRE-CLINICAL MODELS OF NON-GI NEUROPATHIC PAIN
Theanti-allodynicandanti-hyperalgesicpropertiesof gabapentin
and pregabalin have been established in a wide range of ani-
mal models and the literature is too extensive to review here. In
summary, both of these α2δ ligands have been shown to mani-
fest these properties in animal models of inﬂammatory, surgical,
and neuropathic pain, including the inhibition of both the static
and dynamic components of allodynia (for example; Field et al.,
1997a,b, 1999). Interestingly, in a study of both sympathetically-
maintained and sympathetically-independent neuropathic pain,
pregabalin was particularly potent at inhibiting both tactile and
cold allodynia when given by the intrathecal route, suggesting
a predominantly spinal site of action, although the involvement
of supraspinal centers cannot be ruled out (Han et al., 2007).
Pregabalin was unable to inhibit cold allodynia in the model of
sympathetically-independentneuropathicpainwhengivenviathe
intraperitoneal route (Han et al., 2007). Experiments involving
direct recording from spinal neurons have demonstrated the abil-
ityof pregabalintoinhibittheC-ﬁbermediatedresponseof spinal
nociceptive-speciﬁcneurons,withoutanyeffectontheresponsive-
ness of A-δ ﬁbers (You et al., 2009). Further, pregabalin was also
able to inhibit central sensitization of the spinal neurons induced
byapplicationofbeevenom.Spinaltransectionconﬁrmedthatthe
effect of pregabalin in this study was likely to involve supraspinal
centers, mediated through descending inhibitory controls (You
et al.,2009).
PRE-CLINICAL MODELS OF GI SENSATION AND MOTILITY
Following the demonstration of the efﬁcacy of gabapentin and
pregabalin in animal models of neuropathic pain, investigations
oftheproﬁleoftheseagentsinsmallanimalmodelsofvisceralpain
followed. Initial focus was on understanding whether gabapentin
and pregabalin might have utility in the treatment of IBS and so
studies focused on models of rectal or colonic hypersensitivity.
Caution needs to be applied when interpreting these data given
the recent history of notable failure of these models to predict the
effects of other new drugs on human pain and discomfort (e.g.,
those acting at neurokinin-1, NK1, or corticotrophin releasing
factor-1, CRF1, receptors). Despite this in the rat, the intraperi-
toneal administration of lipopolysaccharide (LPS) results, some
9–12h later, in hypersensitivity of the rectum. The hypersensitiv-
ity can be demonstrated following rectal distension with a small
balloon and is manifest as both allodynia as well as hyperalgesia.
In this model, pregabalin, following either oral or intraperitoneal
administration, suppressed the rectal hypersensitivity response to
LPS (Eutamene et al., 2000). Pregabalin (1–30mg/kg p.o.) dose-
dependentlyinhibitedtheallodyniaobservedfollowingdistension
withthelowestvolumeof0.4mL.However,onlythe10mg/kgdose
was able to reduce the nociceptive effect of the larger volumes
of distension. These observations were then extended in a more
chronic model of colonic allodynia (Diop et al.,2002). Seven days
after the administration of trinitrobenzene sulfonic acid (TNBS)
into the proximal colon of the rat, an allodynia to distension
was demonstrated in the distal colon of the animal. Histologi-
cal analysis revealed an inﬂammatory response in the proximal
colon,characterized by the presence of inﬂammatory cells,necro-
sis, and hyperemia, 3days after dosing with TNBS. This response
had substantially diminished by day 7 and in the distal colon, no
increase in inﬂammatory cells was observed at any time point.
Hyperemia appeared to persist to day 7, the study day for these
experiments. Pregabalin (30–200mg/kg s.c.), given 30min prior
to the balloon distension of the distal colon, dose-dependently
reversed the allodynia observed 7days after TNBS administra-
tion. Similar effects were seen following oral administration, 1h
priortoballoondistension.Incontrolanimalsnotpre-treatedwith
TNBS,the highest dose of pregabalin (200mg/kg s.c.),which fully
reversed TNBS-induced allodynia, had no effect on colonic pain
thresholds, in contrast to morphine (0.3 and 1.0mg/kg) which
signiﬁcantly raised thresholds (Diop et al., 2002). In this model,
theinﬂammatorystimulusintheproximalcolonestablishesasec-
ondary hyperalgesia and allodynia in the distal colon,presumably
throughcentralsensitizationatthelevelof thelumbarspinalcord,
althoughpossiblyalsoinvolvinghighercenters.Thesecentralner-
vous system structures are the likely site of action of pregabalin in
this model and in the absence of sensitization, pregabalin had no
effect on sensation.
A series of studies with the prototype α2δ ligand gabapentin,
conﬁrmed that the effects on visceral pain were shared across
the class and not restricted to pregabalin. In both mice and rats,
gabapentinwasshowntoreducetheresponseevokedbyintraperi-
toneal administration of acetic acid, a model of acute visceral
pain.Gabapentin(50–200mg/kgi.p.),dose-dependentlyinhibited
the number of abdominal contractions evoked by intraperitoneal
acetic acid when given 40min ahead of the stimulus (Feng et al.,
2003). The maximum effect was seen at 200mg/kg and inhib-
ited the abdominal response by approximately 75%. This dose
of gabapentin impaired the performance of rats on the beam-
balance test, suggestive of sedation, which can interfere with the
interpretation of tests of analgesia, raising the possibility that the
antinociceptive effect of gabapentin was secondary to sedative
effects. In this study, the investigators also attempted to develop
some mechanistic understanding of these observations and mea-
suredacutechanges(overa90-minobservation)intheintrathecal
levels of several amino acids. Intraperitoneal administration of
acetic acid evoked large rises in both aspartate and glutamate.
These increases were inhibited completely by prior administra-
tion of gabapentin (100mg/kg i.p.). In addition, acetic acid also
increasedtheintrathecallevelsof theinhibitoryaminoacidserine,
an increase that was also inhibited by gabapentin pre-treatment.
Intrathecallevelsoftheinhibitoryaminoacid,glycinewasreduced
to below baseline levels by gabapentin. In a broadly similar study,
this time conducted in mice, Stepanovic-Petrovic et al. (2008)
conﬁrmed the activity of gabapentin to inhibit the nocicep-
tive effects of peritoneal irritation evoked by acetic acid. In this
study,intraperitoneal administration evoked a writhing response,
characterized by abdominal contractions coupled with elonga-
tion of the body and extension of the hindlimbs. Intraperitoneal
administration of gabapentin (10–70mg/kg),1h before the acetic
acid, dose-dependently inhibited the writhing response. Once
again, this group compared the potency of gabapentin to inhibit
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acetic-acid-inducedwrithingwithitsabilitytoimpairmotorfunc-
tion, assessed using the rotarod test (a test of performance in
which the rodent is placed on a suspended horizontal rotating
rod [not high enough to injure the animal but high enough that
the animal avoids falling off] to measure balance, coordination
and motor planning). In this study, gabapentin was devoid of
activity in the rotarod test, even at doses of 2000mg/kg, thus
making it unlikely that the observed antinociceptive effects were
occurringsecondarytosedation.InaninterestingstudyfromMey-
mandiandSepehri(2008),theantinociceptiveeffectofgabapentin
(1–100mg/kg i.p.) was conﬁrmed in the acetic acid-induced
writhing model. In the same study, the dose-response curve to
morphine was also constructed and then a low effective dose of
gabapentin was given as a combination with a sub-therapeutic
dose (0.25mg/kg i.p.) of morphine. This combination produced a
synergisticeffect,aswrithingwasinhibitedbyover90%compared
tocontrollevels.Similarly,whenthesub-therapeuticdoseof mor-
phine was combined with a sub-therapeutic dose of gabapentin
(10mg/kgi.p.),asynergisticresponsewasobserved,withwrithing
inhibited by approximately 70%. Interestingly, these synergistic
effects were not inhibited by treatment with naloxone. Simi-
lar observations, of a synergistic interaction between gabapentin
and morphine in models of visceral pain have been made pre-
viously in a rat model of experimental pancreatitis induced by
bradykinin infusion into the pancreas (Smiley et al., 2004). In
this model, gabapentin (100–300μg intrathecally) only modestly
inhibited the behavioral response to bradykinin. However, when
the 300μg intrathecal dose of gabapentin was combined with
low intrathecal doses of morphine, shown previously to have
modest if any inhibitory effects in this model, signiﬁcant inhi-
bition of all aspects of the behavioral response to bradykinin
was observed. These observations taken together illustrate the
inhibitory effect of gabapentin on visceral pain, strongly sup-
port the concept that this effect is not underwritten or con-
founded by inhibiting arousal and point to potential synergy
with other antinociceptive mechanisms. These data also provide
invivo evidencetosupportthehypothesisthatgabapentinreduces
the release of excitatory and inhibitory neurotransmitters in the
spinal cord.
Recently, a study has been published comparing the effect of
pregabalin in the TNBS model of acute hypersensitivity with
a model of acute hypersensitivity induced by restraint stress
(Ohashi-Doi et al., 2010). As one might predict from previous
data, pregabalin (10–100mg/kg p.o.) reduced colonic nocicep-
tive thresholds dose-dependently in animals sensitized previously
with TNBS. In the stress restraint model, increased fecal output
in terms of number of pellets and fecal weight was observed dur-
ing the period of restraint stress. Pregabalin, over the same dose
range as examined in the TNBS model, also dose-dependently
inhibited the stress-induced increases in fecal output, but had no
effect on naive, unstressed rats. This is the only demonstration
to date that pregabalin can modulate stress-induced defecation in
rats. A comparison of the effects in the two models suggests that
pregabalin may be more potent at inhibiting the stress-induced
increases in defecation than at inhibiting TNBS-induced colonic
hypersensitivity.
The majority of studies of the effects of α2δ ligands on vis-
ceral pain have been restricted to acute models and largely to
those evoked by chemical irritants or pro-inﬂammatory stimuli.
More recently investigators have studied the effects of gabapentin
and pregabalin in models where less invasive and possibly more
physiologically relevant stimuli have been used to evoke an
acute or chronic phenotype. In a rat model, where repeated
tonic colorectal distension induces hypersensitivity, oral prega-
balin(10and30mg/kg)inhibitedthedevelopmentofhyperalgesia
(Million et al., 2007). Moreover, using Fos staining to indicate
neuronal activation, a single oral dose of pregabalin (30mg/kg)
blunted the activation of lumbosacral spinal neurones. These data
raise the possibility that in this model, pregabalin inhibits spinal
sensitization and so inhibits the development of hyperalgesia. It
hasbeendemonstratedthatmaternalseparationofratsintheearly
neonatal period, a presumably highly stressful stimulus, can give
rise to hyperalgesia, revealed by colorectal distension, that is sus-
tained for many weeks after the original stress (Coutinho et al.,
2002) In an elegant study, to date only published as an abstract,
Coelhoetal.(2008)conﬁrmedthatadoseofgabapentin(30mg/kg
s.c.) that inhibited acute visceral pain evoked by intraperitoneal
acetic acid, was also able to inhibit the pain behaviors evoked
by colorectal distension in rats that had undergone maternal
separation 9–11weeks earlier.
New α2δ ligands are starting to appear in literature,but to date,
only one of these, PD-217014, which has similar binding afﬁn-
ity at the α2δ binding site as pregabalin, has been investigated
in an animal model of visceral hypersensitivity (Ohashi et al.,
2008). In the TNBS model described previously, oral dosing of
PD-217014 (3–100mg/kg) dose-dependently inhibited the reduc-
tion in colonic nociception threshold observed 7days after TNBS
administration.Maximuminhibitionwasreachedat60mg/kgand
the inhibition at this dose was long lasting, reaching a peak at
2h post-dose and lasting for between 6 and 8h. Pharmacoki-
netic/pharmacodynamic (PK/PD) analysis clearly demonstrated
that maximum anti-hyperalgesia coincided with peak plasma
exposures. Interestingly, whilst the anti-hyperalgesic effect per-
sisted at 6h post-dose, plasma levels had at this time dimin-
ished to low levels. These observations suggest that the persis-
tence of the pharmacological effect of PD-217014 is not simply
related to plasma exposure and this phenomenon requires further
investigation.
I nar e c e n ts t u d y ,Ravnefjord et al. (2008) demonstrated in
normal, unsensitized rats that pregabalin (10–200μmol/kg p.o.)
inhibited the viscerosomatic response to phasic, noxious colorec-
tal distension at 80mmHg as well as the viscerosomatic response
to ascending (10–80mmHg), phasic distension . In this study, the
highest dose of 200μmol/kg p.o. also inhibited the increases in
cardiovascular parameters (blood pressure and heart rate) seen
in response to noxious distension at 80mmHg. However, one
of the most interesting observations in this study, and one that
reveals another potential mechanism of action of pregabalin to
reducepainthresholdsinthesedistensionmodels,wasanapparent
leftward shift in the colonic pressure-volume relationship. These
observations suggest that pregabalin may increase the compliance
of the colon in response to distension and by this mechanism
could effectively reduce the intensity of the nociceptive stimulus.
Similarly, this could be a mechanistic explanation for the obser-
vations of antinociceptive activity in models employing colorectal
distension as a nociceptive stimulus.
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CLINICAL EVIDENCE AND POTENTIAL UTILITY IN IBS
To date only two clinical studies have been published (Lee et al.,
2005; Houghton et al., 2007) assessing the effect of these com-
pounds on visceral sensitivity in IBS and one abstract in healthy
volunteers(Chuaetal.,2009).Noresultsfromclinicaltrialsexam-
ining the efﬁcacy of α2δ ligands on symptoms in IBS patients
have yet appeared in literature. However,there is one investigator-
sponsored small placebo-controlled trial of pregabalin in IBS
(NCT00977197), another investigator sponsored study looking
at the effect of pregabalin on colonic sensorimotor function in
healthy volunteers (NCT01094808) and a company-sponsored
clinical trial assessing the effect of the new generation α2δ lig-
and,PD-217014inIBS(NCT00139672)currentlylistedontheUS
National Institute of Health ClinicalTrial.gov website.
The ﬁrst study published assessed the effect of gabapentin
(300mg/day for the ﬁrst 3days and the 600mg/day for the sub-
sequent 2days) on rectal sensitivity to balloon distension in IBS
patients with diarrhea diagnosed using Rome II (IBS-D; Lee et al.,
2005).Theauthorsreportedthatthethresholdpressuresforbloat-
ing, discomfort and pain, and rectal compliance all signiﬁcantly
increasedaftergabapentinbutnotfollowingplacebo.Theincrease
in rectal tone seen after meal ingestion was unaffected. Unfortu-
nately however, no direct comparison was made with placebo in
this study, so the signiﬁcance of their gabapentin ﬁndings needs
to be viewed with caution. The second study published by the
authors assessed the effect of pregabalin (titrated from 50mg tid
to 200mg tid over 3weeks) in IBS patients who exhibited rec-
tal hypersensitivity to mechanical distension (Houghton et al.,
2007). In comparison to placebo, pregabalin was shown to sig-
niﬁcantly increase or normalize the sensory thresholds for pain
(anti-allodyniceffect),alongwithﬁrstsensationanddesiretodefe-
cate (anti-hyperalgesic effect), without desensitizing (i.e., make
hyposensitive)theperceptionof distension.If conﬁrmedbylarger
studies and the results from the study currently in progress assess-
ing the effect of pregabalin on colonic sensorimotor function in
healthy volunteers (NCT01094808) proves to be negative, then
this would suggest that as shown in the animal models, desensiti-
zation only occurs in the presence of an hypersensitive state. Such
a compound would be most desirable for treatment of IBS and
conﬁrms studies in healthy volunteers showing that gabapentin
reduces signs of central sensitization induced by intradermal cap-
saicin (i.e., the area of brush and pinprick hyperalgesia) but not
spontaneous or evoked pain induced by capsaicin (Gottrup et al.,
2004). Similarly, a more recent study only published in abstract
form to date, showed that pregabalin prevents the development
of secondary hyperalgesia in the proximal esophagus after dis-
tal esophageal acidiﬁcation but had no effect on the primary
hyperalgesia induced in the distal esophagus (Chua et al., 2009),
supporting a central mode of action for pregabalin in reduction
of pain.
In addition to pregabalin’s effect on visceral sensation, and as
with the gabapentin rectal motor–sensory study (Lee et al., 2005)
andintheanimalmodels(Ravnefjordetal.,2008)describedprevi-
ously, rectal compliance increased following pregabalin, although
there appeared to be no association with the observed reduction
in visceral pain (Houghton et al., 2007). This suggests additional
mechanisms of action, as yet to be explored. Similar observations
havebeenseenbeforewithbothclonidineandnitroglycerineboth
increasing gastric compliance but only clonidine reducing pain
perception (Thumshirn et al.,1999).
Generalized anxiety disorder, as with IBS, is a common dis-
order. Furthermore studies have shown that 32–58% of patients
with IBS meet the diagnostic criteria for GAD (Lydiard, 2001),
a condition which has recently been shown to improve following
treatmentwithpregabalin(Steinetal.,2009).Aswellasimproving
overallanxietylevelsinGADpatients,thestudyshowedthattreat-
mentwithpregabalinalsoledtoanimprovementinGIsymptoms
thatveryoftencoexistinthesepatientsandsimilartothoseseenin
functional GI disorders,such as IBS (Stein et al.,2009). This raises
the possibility that GI symptoms might improve as a consequence
of the treatment of anxiety by pregabalin. Neither the presence of
GAD nor levels of co-existing anxiety or depression were mea-
sured in the study of rectal hypersensitivity (Houghton et al.,
2007), but the observation that pregabalin increased the sensory
thresholds for ﬁrst sensation and the desire to defecate,sensations
notnormallyexpectedtobeundersigniﬁcantpsychologicalinﬂu-
ence, might suggest that the anxiolytic properties of pregabalin
were not playing a major role in modulating visceral sensation. In
support of this hypothesis, other studies using anxiolytic agents,
such as buspirone or antidepressants such as amitryptyline have
shownnoeffectoncolonicsensitivitytoballoondistension(Mertz
et al.,1998;Chial et al.,2003;Morgan et al.,2005). However,these
observations do not exclude the possibility an anxiolytic effect for
pregabalininameliorationof IBSsymptoms,especiallyinpatients
with anxiety-induced increased defecation (as implicated by the
acute restraint stress animal model; Ohashi-Doi et al., 2010), but
clinical trials are required in which psychological symptoms along
with the cardinal IBS symptoms are measured to address the true
efﬁcacy of these agents in the treatment of IBS.
Other factors that might inﬂuence rectal sensation are the
adverseeffectsassociatedwithpregabalin,namelydizzinessand/or
somnolence.However,inthestudyofHoughtonetal.(2007)these
sideeffectshadresolvedinthemajorityofpatientsbythetimesen-
sitivity was assessed, and the change in sensory threshold in these
patients was no different from that seen in those still retaining
mild/moderate side effects, supporting data from animal studies
(Ohashi-Doi et al.,2010).
Furthermore the improvement in sensory threshold tended to
associate with a reduction in abdominal pain (Houghton et al.,
2007), supporting the observations that pregabalin improves GI
symptoms associated with GAD (Stein et al., 2009), and pain in
patients with ﬁbromyalgia (Hauser et al.,2009; Smith and Barkin,
2010; Straube et al., 2010). The results from the ongoing clini-
cal trials are eagerly awaited, and whether the patients have been
appropriatelyphenotypedtoidentifyanysub-groupimprovement
basedontheirhypersensitivityoranxietystatusalsoremainstobe
revealed.
CONCLUSION
Gabapentin and pregabalin are valuable medicines being used
for the treatment of a number of conditions, including neuro-
pathicpain,epilepsy,anxiety,andﬁbromyalgia.Abodyofevidence
implicates binding to the α2δ subunits of voltage-gated calcium
channels on presynaptic neuronal membranes as their most likely
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mechanism of action. However, recent data also points at poten-
tial additional mechanisms within the cell which may underwrite
some of their chronic effects and also indicates potential modula-
tion of pro-inﬂammatory pathways through inhibition of NF-κB
signaling.Themodulationof calciumﬂuxesevokedbygabapentin
and pregabalin has been shown to reduce the release of a broad
range of both excitatory and inhibitory neurotransmitters, pri-
marily in the central nervous system and hence this mechanism
hasgreatpotentialtoinﬂuencesignalingpathways,includingthose
involved in pain transmission. Emerging data supports a role for
the α2δ subunit in neurotransmission in the enteric nervous sys-
tem, but the functional importance of these observations has yet
to be fully elucidated.
Data from animal models provides evidence for the inhibition
of both visceral nociception and GI function by gabapentin and
pregabalin in animals in which hypersensitivity has been induced
byeitheraninﬂammatorystimulusorstress,butlargelyillustrates
an absence of such activity on basal sensitivity or function.
When particularly strong noxious stimuli are used (acetic acid
ordistensiontohighpressures)effectsonsensationinunsensitized
animals can be observed. These observations are in concordance
with earlier experiments performed using isolated in vitro prepa-
rations from animals in which hyperalgesia had been established.
The precise mechanism through which the α2δ ligands inhibit
intestinal allodynia and hyperalgesia has only been hinted at and
much remains as supposition. The extensive literature that indi-
catesthereductioninthereleaseof neurotransmittersatthespinal
and supraspinal level by α2δ ligands remains a valid hypothesis
to explain the observations, with some supporting data obtained
from animal models of visceral pain.
The limited number of clinical studies of visceral pain per-
formed and reported to date support the observations in ani-
mals. In patients with IBS, both gabapentin and pregabalin
have been shown to reduce rectal sensitivity to balloon disten-
sion and in the study with pregabalin, anti-allodynia, and anti-
hyperalgesia was demonstrated in subjects with pre-characterized
rectal hypersensitivity. Data is expected soon from a similar
study in healthy volunteers which will illustrate whether these
agents have, like in many animal models, little effect on sen-
sory thresholds in subjects without hypersensitivity. Both ani-
mal and clinical data also suggest that α2δ ligands may alter
intestinal compliance and the signiﬁcance of this needs further
investigation. These data,supported by observations from animal
studies, support further investigation of α2δ ligands in disorders
characterized by visceral hypersensitivity such as IBS. Carefully
controlled,randomizedclinicaltrialswillbeneededtofullyunder-
stand the potential of these agents to treat these bothersome
conditions.
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